Orthoclone Okt3 — Competitive Intelligence Brief

Orthoclone Okt3 (MUROMONAB-CD3) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD3 Blocker Immunosuppressant. Area: Immunology.

marketed CD3 Blocker Immunosuppressant T-cell surface glycoprotein CD3 Immunology

Target snapshot

Orthoclone Okt3 (MUROMONAB-CD3) — Ortho Biotech.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Orthoclone Okt3 TARGET	MUROMONAB-CD3	Ortho Biotech	marketed	CD3 Blocker Immunosuppressant	T-cell surface glycoprotein CD3	1992-01-01
Talvey	TALQUETAMAB	Janssen Biotech	marketed		T-cell surface glycoprotein CD3	2023-01-01
Epkinly	EPCORITAMAB	Genmab Us, Inc.	marketed	Bispecific CD20-directed CD3 T Cell Engager [EPC]	T-cell surface glycoprotein CD3	2023-01-01
Tzield	TEPLIZUMAB	Provention Bio Inc	marketed	CD3-directed Antibody [EPC]	T-cell surface glycoprotein CD3	2022-01-01
COLUMVI	GLOFITAMAB-GXBM	GENENTECH INC	marketed	Bispecific CD20-directed CD3 T Cell Engager [EPC]	B-lymphocyte antigen CD20, T-cell surface glycoprotein CD3 epsilon chain
TALVEY	TALQUETAMAB-TGVS	JANSSEN BIOTECH	marketed		G-protein coupled receptor family C group 5 member D, T-cell surface glycoprotein CD3
TECVAYLI	TECLISTAMAB-CQYV	JANSSEN BIOTECH	marketed		Tumor necrosis factor receptor superfamily member 17, T-cell surface glycoprotein CD3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD3 Blocker Immunosuppressant class)

1. Ortho Biotech · 1 drug in this class